Kringle PharmaKringle Pharma,Inc.4884東証グロース医薬品FY ending Sep 2025, non-consolidated, J-GAAP

Kringle Pharma FY ending Sep 2020 results

Kringle Pharma brought in ¥467.6M in revenue.

It lost about ¥37 for every ¥100 of sales at the operating level.

Where the money goes

For every ¥100 Kringle Pharma sells, how much goes where, and how much is kept.

FY ending Sep 2020

Margin funnel (derived from reported values)Gross margin 100.0% → Operating margin -36.7% → Net margin -25.2%

Show source documents (4)

EDINET (FSA Japan)
有価証券報告書－第23期(2023/10/01－2024/09/30)
ID S100UZTE2024-12-23Open
EDINET (FSA Japan)
有価証券報告書－第21期(令和3年10月1日－令和4年9月30日)
ID S100PVFJ2022-12-26Open
EDINET (FSA Japan)
有価証券報告書－第20期(令和2年10月1日－令和3年9月30日)
ID S100N50Z2021-12-27Open
EDINET (FSA Japan)
有価証券報告書－第19期(令和1年10月1日－令和2年9月30日)
ID S100KGH22020-12-28Open

Extracted from XBRL: 32 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.